Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy.

ABSTRACT:

Background

To evaluate the survival benefit of neoadjuvant chemotherapy (NAC) in pathologic T2N0 or less patients.

Methods

A total of 526 patients with less than pT2N0 underwent radical cystectomy. Patients were divided into three groups: non-NAC, those who did not receive NAC; partial NAC, those who received less 3 cycles of NAC; and complete NAC, those who received 3 cycles of NAC.

Results

Median follow up was 74.6 (range, 24-311) months. Recurrent-free survival (RFS) was significantly (P=0.041) higher in the non-NAC group than that in the complete NAC group. Overall survival (OS) was significantly (P=0.039) higher in the non-NAC group than that in the complete NAC group. There was no significant difference between the partial NAC group and the complete NAC group. I

SUBMITTER: Yuk HD 

PROVIDER: S-EPMC7354338 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature